共 164 条
[1]
Louis DN(2016)The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary Acta Neuropathol 131 803-820
[2]
Perry A(2009)Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas Acta Neuropathol 118 469-474
[3]
Reifenberger G(2015)IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma Sci Rep 5 16238-2498
[4]
Hartmann C(2015)Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas N Engl J Med 372 2481-2508
[5]
Meyer J(2015)Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors N Engl J Med 372 2499-4546
[6]
Balss J(2017)Isocitrate dehydrogenase-mutant glioma: evolving clinical and therapeutic implications Cancer 123 4535-870
[7]
Kickingereder P(2017)MRI features predict survival and molecular markers in diffuse lower-grade gliomas Neuro Oncol 19 862-117
[8]
Sahm F(2017)Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas Neuro Oncol 19 109-3522
[9]
Radbruch A(2017)Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma Eur Radiol 27 3509-1144
[10]
Brat DJ(2017)Noninvasive assessment of IDH mutational status in World Health Organization grade II and III astrocytomas using DWI and DSC-PWI combined with conventional MR imaging AJNR Am J Neuroradiol 38 1134-398